dapirolizumab pegol

Biogen sees two phase 2 failures: In sciatica and in its lupus collaboration with UCB
Fierce Biogen
Tue, 10/23/18 - 01:40 pm
UCB Pharma
Biogen
dapirolizumab pegol
vixotrigine
lupus
sciatica
UCB, Biogen admit defeat in PhII lupus trial, adding to a string of late-stage failures in the field
Endpoints
Tue, 10/23/18 - 10:37 am
UCB Pharma
Biogen
dapirolizumab pegol
DZP
lupus
clinical trials